9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 606

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Overall Survival (OS),  Objective Response Rate (ORR),  Disease Control Rate (DCR), Composite correlation of PD-L1 expression level and efficacy

Interventions: Nivolumab, Ipilimumab

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: April 15, 2021

Completion Date: April 15, 2022

Last  Posted Date: July 23, 2019

Location: Ucsf, San Francisco, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02899299

Was this article helpful?
Dislike 0